MedTrace Logo

Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime

NCT02533960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3832

Last updated 2023-06-27

No results posted yet for this study

Summary

The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry. It is performed at about 50 certified stroke-units and supported by an unrestricted grant from different pharmaceutical companies to the Heidelberg University Hospital. RASUNOA-Prime is designed to assess the emergency management of acute ischemic and hemorrhagic stroke patients with atrial fibrillation (AF) under different anticoagulation schemes pre stroke: Non-vitamin K antagonist oral anticoagulants (NOAC), Vitamin K antagonists (VKA), and no anticoagulation.

Conditions

Interventions

OTHER

not applicable (observational study)

Observational study without study related intervention.

Sponsors & Collaborators

  • Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

    collaborator INDUSTRY

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Daiichi Sankyo

    collaborator INDUSTRY

  • University of Wuerzburg

    collaborator OTHER

  • University Hospital Heidelberg

    lead OTHER

Principal Investigators

  • Roland Veltkamp, Prof. Dr. med. · Heidelberg University Hospital, Department of Neurology, Heidelberg, Germany; Department of Stroke Medicine, Imperial College London, London, United Kingdom.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2021-01-31
Completion
2022-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02533960 on ClinicalTrials.gov